Results 141 to 150 of about 89,659 (294)

The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme. Rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease [PDF]

open access: bronze, 2000
Salim Yusuf   +97 more
openalex   +1 more source

Water Vapor Energy Therapy Safely Reduces Urinary Medication Use: A Multicenter Retrospective Real‐World Study in Japan (SCCOP Study 24‐01)

open access: yesInternational Journal of Urology, EarlyView.
ABSTRACT Objective The Japanese guidelines for male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) recommend the water vapor energy therapy (WAVE) procedure only for patients in whom conventional BPH surgery is unsuitable due to advanced age or comorbidities.
Junya Abe   +16 more
wiley   +1 more source

The CYP2C19*1/*2 Genotype Does Not Adequately Predict Clopidogrel Response in Healthy Malaysian Volunteers

open access: yesCardiology Research and Practice, 2013
Background. The CYP2C19*2 allele may be associated with a reduced antiplatelet effect for clopidogrel. Here, we assessed whether CYP2C19*2 alleles correlate with clopidogrel responsiveness following the administration of clopidogrel in healthy Malaysian ...
Yanti Nasyuhana Sani   +6 more
doaj   +1 more source

Efficacy of pro‐haemostatic agents in the management of factor Xa inhibitor‐associated intracranial haemorrhages

open access: yesInternal Medicine Journal, EarlyView.
Abstract Background An increasing number of patients in Australia are taking direct oral anticoagulants for a variety of indications since their introduction in the treatment landscape. There has always been some concern about the optimal management approach in the setting of major and/or life‐threatening bleeding.
Sara Shu‐Ling Ng   +4 more
wiley   +1 more source

Clopidogrel resistance and its relevance: Current concepts

open access: yesJournal of Family Medicine and Primary Care
Clopidogrel is the most widely used P2Y12 receptor inhibitor (P2Y12i) as a part of dual antiplatelet therapy along with aspirin. Clopidogrel is a pro-drug and is metabolized to its active metabolite by the hepatic enzyme cytochrome P4502C19 (CYP2C19 ...
Akshyaya Pradhan   +3 more
doaj   +1 more source

Comparison of P2Y12 inhibitors for mortality and stent thrombosis in patients with acute coronary syndromes: Single center study of 10 793 consecutive ‘real-world’ patients

open access: yesPlatelets, 2017
Three oral platelet P2Y12 inhibitors, clopidogrel, prasugrel, and ticagrelor, are available for reducing the risk of cardiovascular death and stent thrombosis in patients with acute coronary syndromes (ACS).
Rebecca Gosling   +7 more
doaj   +1 more source

Safety and Efficacy of a Novel Sealant‐Based Vascular Closure Device Following Electrophysiology Procedures: ReliaSeal Trial

open access: yesJournal of Cardiovascular Electrophysiology, EarlyView.
In a clinical trial of a novel sealant‐based VCD to achieve hemostasis following endovascular procedures, patients randomized to receive the MYNX CONTROL VENOUS VCD had decreased TTH, TTA, and TDE, as compared to patients who received MC. ABSTRACT Background While manual compression (MC) remains the standard of care to achieve hemostasis, a novel ...
John Summers   +15 more
wiley   +1 more source

Clopidogrel pathway [PDF]

open access: yesPharmacogenetics and Genomics, 2010
Katrin, Sangkuhl   +2 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy